Business Context and Reporting Period
Company: CorMedix Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 12, 2021
Reporting Period: Single event date (August 12, 2021)
CorMedix Inc., a Delaware corporation, filed this report to disclose the entry into an At Market Issuance Sales Agreement. The company is listed on The Nasdaq Stock Market LLC under the symbol CRMD.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a capital raising mechanism.
- Proposed Capital Raise: Up to $50,000,000 of common stock.
- Sales Agents: Truist Securities, Inc. and JMP Securities LLC.
- Commission: 3% of the gross sales price per share.
- Offering Type: "At the market offerings" pursuant to Rule 415 under the Securities Act of 1933.
Material Changes
The material change reported is the authorization to sell shares via an "at the market" facility. This agreement allows the company to sell shares from time to time through the designated sales agents using an existing shelf Registration Statement on Form S-3 (Reg. No. 333-249901). No prior comparable period data is provided in this specific filing as it is a current event report rather than a periodic financial statement.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of the Sales Agreement and the filing of a prospectus supplement. It notes that the company has provided customary indemnification and contribution rights to the sales agents.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the standard nature of an equity offering. The actual amount of shares sold, if any, will depend on market conditions and the company's discretion.
Investor Verification Checklist
- Verify the current market price of CRMD to assess potential dilution from the $50,000,000 offering.
- Review the attached Exhibit 1.1 (Sales Agreement) for specific terms regarding termination or volume limits.
- Check subsequent filings to determine if and when shares were actually sold under this agreement.
- Confirm the status of the shelf Registration Statement (Reg. No. 333-249901) referenced in the filing.